LabCorp Announces Agreement to Acquire LipoScience

Acquisition Price of $5.25 Per Share in All Cash Transaction

NMR LipoProfile test expands LabCorp’s offering of personalized diagnostic tests

BURLINGTON, N.C.-- Laboratory Corporation of America^® Holdings (LabCorp^®) (LH) and LipoScience, Inc. (LPDX), a provider of specialized cardiovascular diagnostic laboratory tests based on nuclear magnetic resonance (NMR) technology, today announced that they entered into a definitive merger agreement under which LabCorp would acquire LipoScience for a purchase price of $5.25 per share in cash, or a transaction value of $85.3 million which represents a total enterprise value of approximately $63 million. The Board of Directors of LipoScience has unanimously approved the agreement and recommended approval of the transaction by LipoScience’s stockholders.

Electromed, Inc. Reports a Profit on Higher Fiscal 2014 Fourth Quarter Revenues

NEW PRAGUE, Minn.-- Electromed, Inc. (NYSE MKT: ELMD) today announced financial results for its fourth quarter and fiscal year ended June 30, 2014.

Fourth Quarter Results
Net revenues for the fourth quarter of fiscal 2014 rose 14.8% to $4.6 million, compared with $4.0 million in the fourth quarter of fiscal 2013. Net income was $290,000, or $0.04 per basic and diluted share, compared with a net loss of $416,000, or $0.05 per basic and diluted share, in the same quarter in the prior fiscal year.

ReWalk Robotics Ltd. Announces Pricing of Initial Public Offering

YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Sept. 12, 2014 -- ReWalk Robotics Ltd. (ReWalk), an innovative medical device company that designs, develops and markets wearable robotic exoskeletons for individuals with spinal cord injury, today announced the pricing of its initial public offering of 3,000,000 ordinary shares, at a price of $12.00 per share. ReWalk's ordinary shares are expected to begin trading on September 12, 2014 on the NASDAQ Global Market under the ticker symbol "RWLK." The offering is expected to close on September 17, 2014, subject to the satisfaction of customary closing conditions. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 450,000 ordinary shares at the initial public offering price.

RadNet Reports Record Second Quarter Financial Results and Adjusts Upwards 2014 Guidance Ranges for Revenue and Adjusted EBITDA(1)

• Adjusted EBITDA⁽¹⁾, Income Before Income Taxes and Net Income Per Share are the highest quarterly results in the Company's history
• Adjusted EBITDA⁽¹⁾ increased 11.3%, from $30.0 million in the second quarter of 2013 to $33.4 in the second quarter of 2014
• Sequentially, as compared to the first quarter of 2014, Total Net Revenue ("Revenue") increased 6.0%, and Adjusted EBITDA⁽¹⁾ increased 20.9%
• Earnings Per Share increased from $0.07 per share in the second quarter of 2013 to $0.12 per share in the second quarter of 2014; Income Before Income Taxes increased $3.8 million (excluding non-recurring gains and losses from the sale of imaging centers and Loss on Early Extinguishment of Debt) over last year's second quarter